Patents by Inventor Brian Peter Slingsby

Brian Peter Slingsby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrimidine Derivatives And Their Use As CB2 Modulators
    Publication number: 20100041654
    Abstract: This relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
    Type: Application
    Filed: October 21, 2009
    Publication date: February 18, 2010
    Inventors: Andrew John Eatherton, Gerard Martin Paul Giblin, Richard Howard Green, Jennifer Margaret Doughty, William Leonard Mitchell, Alan Naylor, Derek Anthony Rawlings, Brian Peter Slingsby, Andrew Richard Whittington
  • Pyrimidine derivatives and their use as CB2 modulators
    Patent number: 7635701
    Abstract: The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: December 22, 2009
    Assignee: Glaxo Group Limited
    Inventors: Andrew John Eatherton, Gerard Martin Paul Giblin, Richard Howard Green, Jennifer Margaret Doughty, legal representative, William Leonard Mitchell, Alan Naylor, Derek Anthony Rawlings, Brian Peter Slingsby, Andrew Richard Whittington
  • Pyrrolopyridine derivatives
    Patent number: 7589206
    Abstract: The present invention relates to novel pyrrolopyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: September 15, 2009
    Assignee: Glaxo Group Limited
    Inventors: Andrew John Eatherton, Gerard Martin Paul Giblin, Matthew Russell Johnson, William Leonard Mitchell, Brian Peter Slingsby, Alcide Perboni
  • Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine
    Publication number: 20080132505
    Abstract: Combination of one or more CB2 modulators and one or more PDE4 inhibitors, and method of treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4.
    Type: Application
    Filed: February 1, 2005
    Publication date: June 5, 2008
    Inventors: Andrew James Brown, Helen Elizabeht Connor, Andrew John Eatherton, Gerard Martin Paul Giblin, Richard Howard Green, Jennifer Margaret Doughty, Karamjit Singh Jandu, Richard Graham Knowles, William Leonard Mitchell, Alan Naylor, Celestine Theresa O'Shaughnessy, Giovanni Palombi, Derek Anthony Rawlings, Brian Peter Slingsby, Catherine Jane Tralau-Stewart, Andrew Richard Whittington, Richard Alexander Williamson